Early diagnosis and treatment of Alzheimer’s disease

Recently, focus on early detection, diagnosis and treatment of Alzheimer’s disease (AD) has been increasing. The rationale is that, as with any other serious illness, early intervention will lead to better outcomes for patients and families. Despite the intuitive appeal of this rationale, there is discussion and even debate regarding the issues surrounding early detection and treatment. This review begins with a futuristic case that is aimed at focusing this discussion/debate and then proceeds to consider each of the issues including: should AD screening be part of routine physical examinations? is the amyloid hypothesis correct?: implications for diagnosis and treatment? can neuroimaging studies be used to detect brain amyloid? can symptomatic medications be combined to facilitate cognition? can cognitive rehabilitation programs facilitate cognition? and can immunotherapy and other plaque-busting therapies modify the progression of AD?

[1]  C. Patterson,et al.  Comparison studies of cholinesterase inhibitors for Alzheimer's disease , 2004, The Lancet Neurology.

[2]  Turan M. Itil,et al.  A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia , 1997 .

[3]  D. Selkoe,et al.  Nasal Aβ Treatment Induces Anti‐Aβ Antibody Production and Decreases Cerebral Amyloid Burden in PD‐APP Mice , 2000 .

[4]  Sharona M. Atkins,et al.  Memory enhancement in healthy older adults using a brain plasticity-based training program: A randomized, controlled study , 2006, Proceedings of the National Academy of Sciences.

[5]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[6]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[7]  Johannes Kornhuber,et al.  Therapeutic approaches to Alzheimer's disease. , 2006, Brain : a journal of neurology.

[8]  Masato Taira,et al.  Reading aloud and arithmetic calculation improve frontal function of people with dementia. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[9]  X. Bonfill,et al.  Comparing Self-Management of Oral Anticoagulant Therapy with Clinic Management , 2005, Annals of Internal Medicine.

[10]  C. Rowe,et al.  First results from human studies of a novel F-18 PET ligand for brain {beta}-amyloid imaging , 2007 .

[11]  R. Abbott,et al.  Frequency and characteristics of silent dementia among elderly Japanese-American men. The Honolulu-Asia Aging Study. , 1997, JAMA.

[12]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[13]  P. Aisen,et al.  A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease , 2006, Neurology.

[14]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[15]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[16]  T. Golde.  Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease , 2007 .

[17]  P. Solomon,et al.  Identifying Dementia in the Primary Care Practice , 2000, International Psychogeriatrics.

[18]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[19]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[20]  B. L. Beattie,et al.  Vehicle crash involvement and cognitive deficit in older drivers , 1993 .

[21]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[22]  M. Ball,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories: Concurrences and Cautions , 1997, Neurobiology of Aging.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[24]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[25]  Steven G Potkin,et al.  Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[26]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[27]  K. Ball,et al.  Long-term effects of cognitive training on everyday functional outcomes in older adults. , 2006, JAMA.

[28]  N. Relkin.  Screening and early diagnosis of dementia. , 2000, The American journal of managed care.

[29]  E. Larson,et al.  Dementia in elderly outpatients: a prospective study. , 1984, Annals of internal medicine.

[30]  P. Aisen,et al.  One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline , 2005, American journal of Alzheimer's disease and other dementias.

[31]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[32]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[33]  E. Siemers,et al.  Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. , 2005, Clinical neuropharmacology.

[34]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[35]  D. Selkoe,et al.  Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. , 2003, Annual review of neuroscience.

[36]  M. Etminan,et al.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies , 2003, BMJ : British Medical Journal.

[37]  W. Winkelmayer,et al.  Cardiovascular risk and the thiazolidinediones: déjà vu all over again? , 2007, JAMA.

[38]  Sture Eriksson,et al.  Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study , 2006, The Lancet.

[39]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[40]  D. Kennedy,et al.  The psychopharmacology of herbal extracts: issues and challenges , 2005, Psychopharmacology.

[41]  M. Boustani,et al.  Dementia screening in primary care: is it time? , 2007, JAMA.

[42]  T. Golde.  Alzheimer disease therapy: can the amyloid cascade be halted? , 2003, The Journal of clinical investigation.

[43]  Kathleen N Lohr,et al.  Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2003, Annals of Internal Medicine.

[44]  V. Valcour,et al.  The detection of dementia in the primary care setting. , 2000, Archives of internal medicine.

[45]  A. Kurz,et al.  Potential Biological Markers for Cerebrovascular Disease , 2003, International Psychogeriatrics.

[46]  Soo Borson,et al.  Should older adults be screened for dementia? , 2006, Alzheimer's & Dementia.

[47]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[48]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[49]  E. Rüther,et al.  Diagnosis of dementia in primary care: results of a representative survey in Lower Saxony, Germany , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[50]  H. Fillit,et al.  Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. , 2002, Family medicine.

[51]  Neil B. Minkoff,et al.  Recommendations for best practices in the treatment of Alzheimer's disease in managed care. , 2006, The American journal of geriatric pharmacotherapy.

[52]  J. Marcusson,et al.  Detection of Dementia in Primary Care: The Linköping Study , 2000, Dementia and Geriatric Cognitive Disorders.

[53]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[54]  P. Solomon,et al.  Ginkgo for memory enhancement: a randomized controlled trial. , 2002, JAMA.

[55]  J. Cummings,et al.  Evaluating dementia screening tests , 1999, Neurology.

[56]  P. Solomon,et al.  Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice. , 2005, Geriatrics.

[57]  E. Siemers,et al.  Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers , 2005 .